louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06983236: Exploring Nursing Students' Ability to Create Artificial Intelligence-Enhanced Patient Education Materials on Infection Care
Official title: Exploring Nursing Students' Ability to Create Artificial Intelligence-Enhanced Patient Education Materials on Infection Care: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Nursing Students
Artificial Intelligence (AI)
Patient Education Materials
Randomized Controlled Trial
Keywords: Nursing Students
Artificial Intelligence (AI)
Patient Education Materials
Randomized controlled trial
Lead sponsor: Çankırı Karatekin University
Sponsor class: OTHER
First posted: 2025-05-21
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Maximum age (years): 38
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this study is to explore the ability of nursing students to create artificial intelligence-supported patient education materials regarding infection care. This study will be conducted as a randomized controlled experimental study. Data of the study will be collected with the Descriptive Characteristics Form, Patient Education Information Form and Patient Education Materials Assessment Tool (HEMDA).


Eligibility criteria: Inclusion Criteria:

* To take Basic Principles and Practices in Nursing-II for the first time
* Not to work as a nurse in a hospital or any health institution

Exclusion Criteria:

* Having previously prepared patient education materials;
* Retaking the Basic Principles and Practices in Nursing-II course
* Having difficulty speaking and understanding Turkish;
* Not attending class

Primary outcomes:
measure: Patient Education Information Form
timeFrame: day 6 after the intervention
Secondary outcomes:
measure: Patient Education Materials Assessment Tool (PEMAT-TR)
timeFrame: After the intervention from day 6 to 1 month after intervention
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03088436: Feasibility Study of Supine Breast MRI : Comparison With Prone MRI and Comfort Assessment
Official title: Feasibility Study of Supine Breast MRI : Comparison With Prone MRI and Comfort Assessment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Diseases
Keywords: MRI
Breast
Lead sponsor: Institut de Cancérologie de Lorraine
Sponsor class: OTHER
First posted: 2017-03-23
Enrollment: 47
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients records were extracted from the electronic health record system of Institut de Cancérologie de Lorraine

Brief summary: The aim of the present study was to determine the prone-to-supine displacement of breast lesions using preoperative prone MRI and supine second-look ultrasound data


Eligibility criteria: Inclusion Criteria:

* The inclusion criteria were being a woman with breast lesions whose assessment involved breast MRI and ultrasound at our institution. There were no exclusion criteria.

Exclusion Criteria:

-

Primary outcomes:
measure: distance to the nipple (mm)
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02942836: CareTaker Respiratory Rate Detection Study
Official title: CareTaker Respiratory Rate Detection Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Respiration Rate Detection
Keywords: Respiration Rate Detection
Lead sponsor: CareTaker Medical LLC
Sponsor class: INDUSTRY
First posted: 2016-10-24
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Subjects were local health club members, \> 18 years of age, who were able and willing to participate and willing to sign the written consent

Brief summary: The goal of the proposed study is to test the capability of the CareTaker monitor to extract the respiration signature from its acquired signal, and to determine a respiration rate of breaths/minute that meets or exceeds the performance levels of its predicate device.

Detailed description: The goal of the proposed study is to test the capability of the CareTaker monitor to extract the respiration signature from its acquired signal, and to determine a respiration rate of breaths/minute that meets or exceeds the performance levels of its predicate device.

The detection approach of RSPR (respiratory rate) that the CareTaker technology takes is based on peak detection and pulse analysis of arterial pressure pulse signals, as well as spectral analysis of the raw CareTaker sensor signal.

The study was performed under the supervision of the Chesapeake IRB and involved 21 subjects \>18 y who were monitored during spontaneous and metronome-paced breathing.

Eligibility criteria: Inclusion Criteria:

* \> 18 years of age, who are able and willing to participate and have given verbal assent

Exclusion Criteria:

* Unable to give written consent
* \<18 years of age
* No or poor finger pulse, as determined through visual inspection for ischemic hands

Primary outcomes:
measure: Respiration rate detection with accuracy of better than 3 breaths per minute
timeFrame: 15 minutes of matched respiration rates
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: CareTaker Medical LLC
name: Martin C Baruch, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05892536: Regenerative Endodontics in Mature Permanent Teeth
Official title: Evaluation of the Effect of Photobiomodulation on Revascularization of Mature Non-vital Permanent Teeth Using Blood Clot as Scaffold
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Regenerative Endodontics
Lead sponsor: Minia University
Sponsor class: OTHER
First posted: 2023-06-07
Enrollment: 24
Sex: ALL
Minimum age (years): 9
Maximum age (years): 13
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: this study was designed to compare the clinical and radiographic success of REPs after using blood clot scaffold in non-vital mature permanent teeth with or without photobiomodultion therapy


Eligibility criteria: Inclusion Criteria:

* Patients free from any systemic diseases or genetic disorders.
* Children aged 9-13 years old of both sexes.
* Traumatically or cariously exposed single rooted mature permanent teeth which may be asymptomatic or manifested with dull ache pain, or spontaneous unprovoked toothache.
* Non-vital single rooted mature permanent teeth that indicated for endodontic treatment
* Swelling close to involved tooth accompanied with or without fistula.
* Negative response to cold \& electrical pulp test.
* Informed Consent.

Exclusion Criteria:

* Unrestorable teeth, or that need post and core for the final restoration.
* Immature permanent teeth.
* Known allergy, sensitivity to ciprofloxacin, metronidazol.
* Uncooperativeness of child and/or parents or caregiver's behavior.
* Presence of calcific metamorphosis inside root canals.

Primary outcomes:
measure: Pulp sensibility
timeFrame: Every 3 months over a period of one year
measure: Radiographic evaluation of periapical tissues
timeFrame: Every 3 months over a period of one year
Secondary outcomes:
Other outcomes:
Locations:
city: Minya
country: Egypt
facility: Minia University
Study officials:
affiliation: Minia University
name: salma khattab, master
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05363436: Opioid Reduction Toolkit Reduces Opioids Prescribed and Consumed
Official title: Successful Implementation of an Opioid Reduction Toolkit in Pancreatectomy Patients Significantly Decreases Number of Opioids Prescribed and Consumed
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE4
Conditions: Opioid Abuse
Opioid Misuse
Pain
Lead sponsor: Thomas Jefferson University
Sponsor class: OTHER
First posted: 2022-05-05
Enrollment: 159
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Control group, measurement, intervention group
Primary purpose: PREVENTION

Brief summary: Investigators studied a baseline population of patients receiving pancreatectomies at their institution and determined how many opioid pills each patient was prescribed and how many they took. Based on this data they created a toolkit to provide to prescribers to give patients a modified number of pills. The amount prescribed and consumed was measured after intervention.

Detailed description: A single academic surgical department reviewed opioid treatment patterns for patients undergoing common procedures, including open pancreatectomy, and an opioid reduction toolkit using the data collected was created. Providers were educated on the use of the toolkit and it was implemented as a standard of practice. Data were collected on pancreatectomy patients via telephone interview (performed at 2 weeks post-op) and by reviewing the state prescription drug monitoring program. Outcome variables included morphine milliequivalents (MME) of pills prescribed, MME of pills consumed, number of patients aware of proper unused pill disposal, number of patients requesting refills, and pain scores. Categorical and continuous outcomes were compared within and between groups.

Eligibility criteria: Inclusion Criteria:

* Age \> 18
* Being scheduled for an outpatient elective pancreatectomy

Exclusion Criteria:

* Urgent/emergent status
* Concomitant procedure being performed at time of pancreatectomy

Primary outcomes:
measure: Number of opioid pills reported being taken by the patient
timeFrame: 14 days
measure: Number of opioid pills being prescribed
timeFrame: 14 days
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Thomas Jefferson University Hospital
state: Pennsylvania
Study officials:
References:
Clinical trial NCT04900636: Telemedicine for Patients With an Hybrid Closed Loop System
Official title: A Telemedicine Platform for Patients With Type 1 Diabetes Mellitus Treated With an Hybrid Closed Loop System
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus, Type 1
Lead sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Sponsor class: OTHER
First posted: 2021-05-25
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective is to assess the impact on quality of life after a follow-up program using a telemedicine platform designed for patients with DM1 treated with an hybrid closed loop insulin infusion system. Open-label, randomized 1:1 controlled clinical trial during 12 months.


Eligibility criteria: Inclusion Criteria:

* Diagnostic criteria for DM1 according to ADA
* They must have access to the technology that allows monitoring (mobile phone and / or computer as well as having an internet connection)
* Acceptance of participation in the study and signing of the informed consent

Exclusion Criteria:

* Gestation
* Institutionalization, serious or terminal illness or renal replacement therapy.
* Inability to undertake the training and / or acquire the degree of knowledge to use the telemedicine platform.
* Refusal to participate in the study or to sign the informed consent

Primary outcomes:
measure: Impact on quality of life
timeFrame: 12 months
Secondary outcomes:
measure: Metabolic control
timeFrame: 12 months
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Lía Nattero Chávez
state: Please Select
Study officials:
affiliation: Hospital Ramón y CajaDiabetes, Obesity and Human Reproduction Research Group, Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)
name: Lía Nattero Chávez, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00561236: Does Intravitreal Injection of Triamcinolone Acetonide Impairs the Adrenal Function
Official title: Low Dose (1mcg ) ACTH Stimulation Test for Assessment of the Hypothalamo- Pituitary- Adrenal Axis in Patients Treated With Intravitreal Injection of Triamcinolone Acetonide
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Secondary Adrenal Insufficiency
Lead sponsor: HaEmek Medical Center, Israel
Sponsor class: OTHER
First posted: 2007-11-20
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: hospital-based ophtalmologic clinic

Brief summary: The use of intravitreal corticosteroids in the management ocular inflammatory diseases has recently gained widespread acceptance. The purpose of this study is to determine if the use of intravitreal triamcinolone is associated with suppression of endogenous cortisol production, as generally admitted for patients treated with oral or parenteral corticosteroid therapy.

Detailed description: The normalcy of hypothalamic- pituitary- adrenal axis (HPA axis) of enrolled subjects will will be assessed before intravitreal injection of 4mg of triamcinolone and again after one day, one week and two weeks. Patients with abnormal HPA axis will be re-tested after four weeks and later until the HPA axis function return to normal. The HPA axis will be assessed with low dose (1mcg) intravenous corticotropin(ACTH) stimulation test, in which cortisol levels will be sampled before , 30 minutes and 60 minutes after 1mcg ACTH IV injection.

Eligibility criteria: Inclusion Criteria:

* patients receiving intravitreous injection of triamcinolone 4mg

Exclusion Criteria:

* patients receiving steroids in any form, except by intravitreous administration

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Afula
country: Israel
facility: Haemek Medical Center
Study officials:
affiliation: Haemek Medical Center , Endocrine Institute
name: Avraham Ishay, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03886636: Neuroscience Pain Education in Patients with Chronic Low Back Pain
Official title: The Effectiveness of Neuroscience Pain Education Combining Manual Therapy in Patients with Chronic Low Back Pain: a Single-blinded Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Low Back Pain
Manual Therapy
Neuroscience Pain Education
Lead sponsor: Kutahya Health Sciences University
Sponsor class: OTHER
First posted: 2019-03-22
Enrollment: 69
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The cognitive educational strategies such as neuroscience pain education, has been a popular and promising technique for treatment patients with chronic pain. However, there are not sufficient randomized controlled and blinded studies to explore clinical effectiveness of these techniques. Therefore, the aim of this study was determining the short- and mid-term effects of neuroscience pain education combined with manual therapy and home exercise on pain level, disability, and kinesiophobia in patients with chronic low back pain.


Eligibility criteria: Inclusion Criteria:

* Volunteered to participate in the study.
* Patients with 18-65 years
* Had low back pain for at least 6 months,
* Reported pain severity of 5 or greater according to the numeric pain rating scale
* Used pregabalin and gabapentin derivatives,

Exclusion Criteria:

* Previous spine or lower extremity surgery
* Severe osteoporosis
* Spondyloarthropathy
* Spondylolisthesis
* Lumbar stenosis
* Systemic inflammatory diseases

Primary outcomes:
measure: Numeric pain rating scale (NPRS)
timeFrame: Change from Baseline NPRS at 4th weeks and 12th weeks
Secondary outcomes:
measure: Oswestry Disability Index (ODI)
timeFrame: Change from Baseline ODI at 4th weeks and 12th weeks
measure: Back Performance Scale (BPS)
timeFrame: Change from Baseline BPS at 4th weeks and 12th weeks
measure: Tampa Scale for Kinesiophobia (TSK)
timeFrame: Change from Baseline TSK at 4th weeks and 12th weeks
Other outcomes:
Locations:
city: Kutahya
country: Turkey
facility: Yoncali Physical Therapy and Rehabilitation Hospital
Study officials:
References:
Clinical trial NCT04734236: Development of Molecular Diagnostic Platform for Tuberculosis
Official title: Development of a Rapid and Accurate Diagnostic Assay for Tuberculosis by Using New Sample Preparation and Detection Technique
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Tuberculosis
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2021-02-02
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This study evaluates new technique for diagnosis of tuberculosis. Among patients who are suspected with tuberculosis, participants will be tested conventional method including Xpert TB/RIF assay, and new diagnostic technique using homobifunctionalImidoesters compounds.


Eligibility criteria: Inclusion Criteria:

* Patients who are suspected with pulmonary tuberculosis, tuberculosis meningitis, tuberculosis peritonitis, tuberculosis pleurisy

Exclusion Criteria:

* Under 18 years

Primary outcomes:
measure: The effectiveness of new diagnostic technique
timeFrame: Time Frame: An average of 2 year
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center, University of Ulsan College of Medicine
state: Songpa
Study officials:
References:
Clinical trial NCT03185936: Surgical Management of Optic Disc Pit Maculaopathy
Official title: Pars Plana Vitrectomy With Internal Limiting Membrane Peeling in Optic Disc Pit Maculopathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Optic Disc Structural Anomaly
Maculopathy
Keywords: optic disc pit
retinal detachment
maculopathy
Lead sponsor: Minia University
Sponsor class: OTHER
First posted: 2017-06-14
Enrollment: 9
Sex: ALL
Minimum age (years): 15
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the anatomical and functional results of pars plana vitrectomy (PPV) combined with internal limiting membrane (ILM) peeling, endolaser photocoagulation and gas tamponade in management of optic disc pit (ODP) maculopathy.

Detailed description: As it is well known, optic disc pit (ODP) is a rare congenital disease which is usually associated with maculopathy (ODP-M) in the form of intraretinal and subretinal fluid accumulation at the macular area leading to visual impairment.

With no definite treatment and absence of guidelines for its management, the invistigators considered their prospective, interventional case series to evaluate the anatomical and functional results of pars plana vitrectomy (PPV) combined with internal limiting membrane (ILM) peeling, endolaser photocoagulation and gas tamponade in management of optic disc pit (ODP) maculopathy.

Eligibility criteria: Inclusion Criteria:

* Patients included in this study are those with ODP associated with macular detachment

Exclusion Criteria:

* Exclusion criteria included patients unfit for general anesthesia, those with insufficient clear media to perform the surgery with ILM peeling and those with other ocular diseases that can affect central macular thickness (CMT) and the best corrected visual acuity (BCVA).

Primary outcomes:
measure: anatomical improvement
timeFrame: 6 months
Secondary outcomes:
measure: Functional improvement
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
affiliation: Assistant professor of ophthalmology, ophthalmology department, Minia university, Egypt
name: Mahmud Genaidy, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00848536: Efficacy Study of Travoprost APS Versus TRAVATAN
Official title: A Multi-Center, Double-Masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATAN® in Patients With Open-Angle Glaucoma or Ocular Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Open Angle Glaucoma
Ocular Hypertension
Keywords: OAG
OHT
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2009-02-20
Enrollment: 371
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Multi-Center Double-masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATAN in Patients with Open-angle Glaucoma or Ocular Hypertension


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older, either gender and any race.
* Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT).
* Not currently on any IOP-lowering medication or currently on a stable treatment (i.e, at least 30 days) with and IOP-lowering monotherapy.
* All patients: Mean IOP in same eye (at both Eligibility 1 \& 2 Visits):

  ≥ 24 and ≤ 36 mmHg at 9 AM; and ≥ 21 and ≤ 36 mmHg at 11 AM \& 4 PM.
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Females of childbearing potential not meeting conditions set in the protocol.
* Severe central visual field loss.
* Angle Shaffer grade \< 2.
* Cup/disc ratio \> 0.8 (horizontal or vertical measurement).
* Best corrected visual acuity (VA) score worse than 55 ETDRS letters read (equivalent to approximately 20/80 Snellen or 0.25 decimal).
* Intraocular surgery or trauma within last 6 months.
* Any abnormality preventing reliable applanation tonometry.
* History of or current ocular pathology (including severe dry eye) that would affect the conduct of the study.
* Allergy/hypersensitivity to study medications.
* Unable to discontinue use of all IOP-lowering medications for a minimum wash-out period of 5 to 28 days prior to the Eligibility Visit.
* Less than 30 days stable dosing regimen of medications used on a chronic basis that may affect IOP.
* Use of any additional topical or systemic ocular hypotensive medication during the study.
* Therapy with another investigational agent within 30 days prior to the Screening visit.
* Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Mean Intraocular Pressure at 9:00 am
timeFrame: 3 months (measured at 9:00 am)
measure: Mean Intraocular Pressure at 11:00 am
timeFrame: 3 months (measured at 11:00 am)
measure: Mean Intraocular Pressure at 4:00 pm
timeFrame: 3 months (measured at 4:00 pm)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: